- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07688369
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is a double-blinded, randomised, active controlled, Phase 1 clinical study, to determine the safety, tolerability, and reactogenicity of Serum Institute of India Pvt Ltd (SIIPL) rPV vaccine in comparison to the commercially available inactivated poliovirus vaccine (IPOL®, Sanofi) in up to 36 healthy adults aged between 18 and 60 years. This study will be conducted at a single study site in Australia.
Participants will be randomised in a 2:1 ratio, to receive either investigational vaccine (rPV) or comparator vaccine (IPOL), respectively. The study vaccine will be administered as a single intramuscular (IM) injection into the deltoid muscle of the non-dominant upper arm. The participants will be followed for 30 days post vaccination.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Dr Hitt Sharma, MBBS MBA
- Telefonnummer: +91-9822418354
- E-post: drhjs@seruminstitute.com
Studera Kontakt Backup
- Namn: Dr Sameer Parekh, MBA
- Telefonnummer: +91-9226722745
- E-post: sameer.parekh@seruminstitute.com
Studieorter
-
-
Victoria
-
East Melbourne, Victoria, Australien, 3002
- Rekrytering
- Doherty Clinical Trials Limited
-
Kontakt:
- Nicola Byrne
- Telefonnummer: +61 03 9970 4200
- E-post: nbyrne@dohertyclinicaltrials.com
-
Huvudutredare:
- Dr Gail Cross, MBBS FRACP PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Healthy Volunteers aged between 18 to 60 years inclusive.
- Good physical and mental health based on medical history, physical examination, clinical laboratory,electrocardiogram (ECG), and vital signs, as judged by the Investigator.
- Participants must refrain from strenuous exercise within 96 hours (4 days) prior to Screening, Day 1, Day 8,and Day 30..
- Willing and able to comply with restrictions of nicotine (i.e., tobacco and nicotine products) usethroughout the study is not permitted from within 48 hours (2 days) prior to Screening, from Day 1 until Day8, and within 48 hours (2 days) prior to the end of study visit.
- Participants must agree to use highly effective contraception from Day 1 until 90 days after the last studyvisit.
Key Exclusion Criteria:
- History of Polio
- Any vaccination received 30 days before Screening and Day 30
- Pregnant or lactating females
- BMI >35.0kg/m2
- History of alcohol abuse or drug addiction
- Have received any polio vaccines within 6 months prior to screening.
- History of major surgeries
- History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior tostudy vaccination
- any confirmed or suspected congenital or acquired immunosuppressive or immunodeficient condition.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Recombinant Poliomyelitis Vaccine (rPV)
|
Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd. |
|
Aktiv komparator: Inactivated Poliomyelitis Vaccine (IPOL)
|
IPOL (inactivated poliovirus vaccine) is a marketed Sanofi |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
The incidence, severity and relationship of solicited adverse events (AEs) during 7-day and unsolicited AEs during 30-day follow-up period after rPV and IPOL vaccination
Tidsram: 30 days
|
30 days
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Percentage of participants achieving seroprotection/seroconversion for poliovirus Types 1, 2 and 3, on Day 30.
Tidsram: 30 days
|
30 days
|
Samarbetspartners och utredare
Utredare
- Studierektor: Dr Hitt Sharma, MBBS MBA, Serum Institute of India Pvt. Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neuroinflammatoriska sjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neuromuskulära sjukdomar
- Infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Ryggmärgssjukdomar
- Infektioner i centrala nervsystemet
- Myelit
- Polio
- Biologiska produkter
- Komplexa blandningar
- Vacciner
- Virala vacciner
- Vacciner, inaktiverade
- Poliovirusvacciner
- Poliovirusvaccin, inaktiverat
Andra studie-ID-nummer
- SII-rPV-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Summary results
Tidsram för IPD-delning
12 months after completion of the study
Kriterier för IPD Sharing Access
Researchers who provide a methodologically sound proposal may be provided the access afterSponsor permission and if signed data-access agreements are in place.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .